The market has been neutral on Exelixis, Inc. (EXEL) stock recently. EXEL gets a EXEL score from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With EXEL Stock Today?
Exelixis, Inc. (EXEL) stock has fallen -0.05% while the S&P 500 has risen 0.06% as of 1:05 PM on Tuesday, Feb 16. EXEL is down -$0.01 from the previous closing price of $21.91 on volume of 1,908,768 shares. Over the past year the S&P 500 has risen 16.82% while EXEL has risen 3.16%. EXEL earned $0.35 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 62.55.
To screen for more stocks like Exelixis, Inc. click here.
More About Exelixis, Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced renal cell carcinoma, or kidney cancer, and hepatocellular carcinoma, or liver cancer (as Cabometyx). Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma.
Click Here to get the full Stock Score Report on Exelixis, Inc. (EXEL) Stock.
